NCT04907968 - Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer | Biotech Hunter

Enrollment

31

Participants

Timeline

Start Date

June 11, 2021

Primary Completion Date

October 3, 2023

Study Completion Date

October 3, 2023

Conditions

Platinum-sensitive Ovarian Cancer (UPGRADE-A)

Interventions

DRUG

XMT-1536 (Upifitamab Rilsodotin)

"Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~* XMT-1536~* UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles."

DRUG

Carboplatin

"Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~* XMT-1536~* UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles."

Trial Locations (1)

49546

START Midwest, Grand Rapids